首页> 外文期刊>Bone marrow transplantation >High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma.
【24h】

High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma.

机译:异基因造血干细胞移植后强度降低的条件疗法治疗晚期恶性淋巴瘤的完全反应率高。

获取原文
获取原文并翻译 | 示例
       

摘要

Summary:The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n=9) or aggressive lymphoma (n=11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.Bone Marrow Transplantation (2003) 32, 131-137. doi:10.1038/sj.bmt.1704118
机译:摘要:同种异体造血干细胞移植(allo-HSCT)的可能优势是移植物抗淋巴瘤的作用。我们探讨了在晚期恶性淋巴瘤(ML)中采用降低强度(RI)方案的同种-HSCT的可行性和疗效。共有20例惰性(n = 9)或侵袭性淋巴瘤(n = 11)患者接受了RI方案(RIST)的all-HSCT。制备方案由嘌呤类似物和烷基化剂联合或不联合抗胸腺细胞球蛋白组成。共有11例患有化学难治性疾病,7例具有化学敏感性复发性疾病,2例具有残留性疾病。所有患者均从HLA匹配的兄弟姐妹接受了G-CSF动员的血液干细胞。在20例患者中,有19例接受了与方案相关的可接受毒性的移植。 7例患者发展为II-IV级急性GVHD,15例发展为慢性GVHD。在15例可评估疾病患者中,有12例完全缓解。 1例死于侵袭性镰刀菌病,4例死于GVHD并发真菌感染,1例死于进行性疾病。 Kaplan-Meier平均随访358天,对1年总生存期和无进展生存期的估计均为70%。在这项研究中观察到的高响应率和低复发率提示RIST可能是晚期ML患者的一种有效的替代治疗方法。骨髓移植(2003)32,131-137。 doi:10.1038 / sj.bmt.1704118

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号